Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma

被引:15
|
作者
Blakeley, Jaishri [1 ]
机构
[1] Johns Hopkins Univ, Baltimore, MD 21204 USA
关键词
antiangiogenesis; drug; mTOR; neurofibromatosis type 2; NF2; TUMOR-SUPPRESSOR; DIAGNOSTIC-CRITERIA; ACTIVATION; INHIBITION; GROWTH; BEVACIZUMAB; MERLIN; ANGIOGENESIS; THERAPIES; CANDIDATE;
D O I
10.1097/MOO.0b013e328357d2ee
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Purpose of review To review the discoveries in molecular pathophysiology contributing to the development of neurofibromatosis type 2 (NF2)-associated vestibular schwannomas and the recent experiences with drug therapies for these tumors. The review includes discussion of diagnostic criteria for NF2, populations to clinically consider for drug therapy and drug targets currently under consideration for NF2. Recent findings Increased insight into the complex pathways that underlie both the genetic syndrome of NF2 and the specific pathogenesis of vestibular schwannomas has highlighted multiple potential therapeutic targets. These discoveries have been translated into clinical trials with some early promising results. Inhibition of angiogenesis as well as regulation of mammalian target of rapamycin and the epidermal growth factor receptor family of receptors are the focus of current clinical investigations. Summary Although a great deal of work is ongoing to understand the multiple effects of the lack of the regulating protein Merlin on tumorgenesis in patients with NF2, advances are ongoing with clinical therapeutics. There is cause for enthusiasm based on recent results with antiangiogenesis therapy in select patients with NF2 and progressive vestibular schwannomas; however, awareness of the notable risks and limitations of therapies currently in development is required.
引用
收藏
页码:372 / 379
页数:8
相关论文
共 50 条
  • [1] Serial analysis of gene expression in neurofibromatosis type 2-associated vestibular schwannoma
    Halum, SL
    Popper, P
    Cioffi, JA
    Wackym, PA
    [J]. OTOLOGY & NEUROTOLOGY, 2004, 25 (04) : 587 - 593
  • [2] Cochlear Implant Outcomes between Patients with Sporadic and Neurofibromatosis Type 2-Associated Vestibular Schwannoma
    Dornhoffer, James R.
    Haller, Travis
    Lohse, Christine M.
    Driscoll, Colin L. W.
    Neff, Brian A.
    Saoji, Aniket
    Link, Michael J.
    Carlson, Matthew L.
    [J]. OTOLOGY & NEUROTOLOGY, 2023, 44 (08) : 791 - 797
  • [3] Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas
    Jiramongkolchai, Pawina
    Schwartz, Marc S.
    Friedman, Rick A.
    [J]. OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2023, 56 (03) : 533 - 541
  • [4] Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas
    Dewan, Ramita
    Pemov, Alex
    Kim, H. Jeffrey
    Morgan, Keaton L.
    Vasquez, Raul A.
    Chittiboina, Prashant
    Wang, Xiang
    Chandrasekharappa, Settara C.
    Ray-Chaudhury, Abhik
    Butman, John A.
    Stewart, Douglas R.
    Asthagiri, Ashok R.
    [J]. NEURO-ONCOLOGY, 2015, 17 (04) : 566 - 573
  • [5] Tyrosine nitration induces a metabolic reprogramming in neurofibromatosis type 2-associated Schwannoma cells
    Pestoni, Jeanine
    Camacho, Oliver Valdivia
    Riordan, Ruben
    Kim, Sharon
    Fernandez-Valle, Cristina
    Franco, Maria Clara
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2018, 128 : S91 - S91
  • [6] Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
    Fujii, Masazumi
    Ichikawa, Masahiro
    Iwatate, Kensho
    Bakhit, Mudathir
    Yamada, Masayuki
    Kuromi, Yosuke
    Sato, Taku
    Sakuma, Jun
    Saito, Kiyoshi
    [J]. NEUROLOGIA MEDICO-CHIRURGICA, 2020, 60 (02) : 75 - 82
  • [7] Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis
    Huang, Qiao
    Zhai, Si-Jia
    Liao, Xing-Wei
    Liu, Yu-Chao
    Yin, Shi-Hua
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [8] NEUROFIBROMATOSIS TYPE-2 WITHOUT VESTIBULAR SCHWANNOMA
    MAUTNER, VF
    LINDENAU, M
    KOPPEN, J
    HAZIM, W
    KLUWE, L
    [J]. ZENTRALBLATT FUR NEUROCHIRURGIE, 1995, 56 (02): : 83 - 87
  • [9] New developments in neurofibromatosis type 2 and vestibular schwannoma
    Ren, Yin
    Chari, Divya A.
    Vasilijic, Sasa
    Welling, D. Bradley
    Stankovic, Konstantina M.
    [J]. NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
  • [10] Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2
    Wagner, J.
    Welzel, T.
    Habermehl, D.
    Debus, J.
    Combs, S. E.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 82 - 82